Clinical evaluation of ceftazidime in Japan.
Ceftazidime has been evaluated in a total of 1548 cases of infection involving medical and surgical patients. Most of the cases were treated with 1 to 2 g/day. Of the total number of assessable cases (1418), over 80% responded satisfactorily (1141). Bacterial eradication was achieved in 850 cases (81% of those assessable). The incidence of adverse events was low (2.1%) being observed in 32 cases out of 1529 that were assessable. Clinical events were mainly skin eruptions, nausea and vomiting. Laboratory abnormalities were mainly slight elevations of serum GOT, GPT, alkaline phosphatase and eosinophil counts.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002442:Ceftazidime; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use*; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D012141:Respiratory Tract Infections / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy; D013530:Surgical Wound Infection / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy; D014839:Vomiting / Q000139:chemically induced
D002511:Cephalosporins; D002442:Ceftazidime